Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy

Vaghasiya, Kalpesh; Ray, Eupa; Singh, Raghuraj; Jadhav, Krishna; Sharma, Ankur; Khan, Rafaqat Ali; Katare, Om Prakash; Verma, Rajkumar

doi:10.1016/j.msec.2021.112027

Cited by 58 publications

(24 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Verma designed a smart inhalable nanocarrier by complexation of gelatin with cisplatin for lung tumor therapy. After the degradation of gelatin, cisplatin was exposed to physiological salts and exchanged with chloride ions, leading to the fast release of cisplatin at the tumor site [ 79 ].…”

Section: Enzyme-responsive Nanocarriersmentioning

confidence: 99%

Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer

Liu

et al. 2022

Molecules

View full text Add to dashboard Cite

Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide. Numerous drugs have been developed to treat lung cancer patients in recent years, whereas most of these drugs have undesirable adverse effects due to nonspecific distribution in the body. To address this problem, stimuli-responsive drug delivery systems are imparted with unique characteristics and specifically deliver loaded drugs at lung cancer tissues on the basis of internal tumor microenvironment or external stimuli. This review summarized recent studies focusing on the smart carriers that could respond to light, ultrasound, pH, or enzyme, and provided a promising strategy for lung cancer therapy.

show abstract

Section: Enzyme-responsive Nanocarriersmentioning

confidence: 99%

Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer

Liu

et al. 2022

Molecules

View full text Add to dashboard Cite

show abstract

“…Finally, while antibodies are most commonly associated with antigen targeting, ADCs are also being developed to conjugate cytotoxic drugs to tumor-specific receptor ligands. While these targeting modalities are not covered in this review, we point readers to these recently published reviews [191][192][193][194][195].…”

Section: Novel Target Antigensmentioning

confidence: 99%

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective

et al. 2021

View full text Add to dashboard Cite

Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA approvals in the last two years and a projected market value of over $4 billion by 2024. Major advancements in the engineering of these novel cytotoxic drug carriers have provided a few early success stories. Although the use of these immunoconjugate agents are still in their infancy, valuable lessons in the engineering of these agents have been learned from both preclinical and clinical failures. It is essential to appreciate how the various mechanisms used to engineer changes in ADCs can alter the complex pharmacology of these agents and allow the ADCs to navigate the modern-day therapeutic challenges within oncology. This review provides a global overview of ADC characteristics which can be engineered to alter the interaction with the immune system, pharmacokinetic and pharmacodynamic profiles, and therapeutic index of ADCs. In addition, this review will highlight some of the engineering approaches being explored in the creation of the next generation of ADCs.

show abstract

“…Cell viability (%) = OD Sample /OD Control ×100% (5) where the OD Sample and OD Control were the optical density (OD) of samples and negative controls, respectively. The Student's t-test proceeded to verify the signi cance of any statistical differences, and all quantitative data were shown as the form of mean ± SD value.…”

Section: In Vitro Cytotoxicity Assaymentioning

confidence: 99%

“…Free PTX and PTX-encapsulated S1 ~ S4 nanomicelles were seeded in a 6-well plate containing 1×10 5 Colon-26 cells per well and cultured. After 24 h, the initial medium was removed, following the supplemention of new medium with 30 µg ml − 1 of PTX and incubation for 6 h. The cells were xed by 4% paraformaldehyde and rinsed using PBS thrice.…”

Section: Celluar Uptakementioning

confidence: 99%

“…[1][2][3] Although these carriers are constructed based on the abnormal physiological signals at the tumor site such as pH, temperature, enzyme, hypoxia, and redox components, etc., which still produce severe defects including retard, explosive, lagged, and even uncontrolled release. [4][5][6][7][8] Tumors at different stages showed varied demand for drugs, but no markedly discriminate release behavior of existing nanovehicles can result in low drug utilization and severe side effects. [9] In previous studies, single stimuli-responsive drug nanovehicles were designed but possessed unsatisfactory release behavior due to limited response functional groups contained and inaccurate controllable capacity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tuning Paclitaxel Release Behavior Using Dually-Responsive Nanomicellar Assemblies with Multiple Diselenide/Disulfide Linkages

Yan

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: There are many reasons that lead to the failure of cancer chemotherapy, such as uncontrolled drug release, low drug utilization, and severe side effects. Methods: To overcome these obstacles, we designed two kinds of copolymers with thermal and redox-responsive properties containing multiple diselenide/disulfide bonds polyethylene glycol -alt- diselenodipropionate/disulfhydryldipropionate-b-poly(N-isopropylacrylamide) (abbreviated as PEG-alt-DSeDP-b-PNIPAM and PEG-alt-DSDP-b-PNIPAM) by alternative esterification and following atom transfer radical polymerization. Afterward, these prepared copolymers were mixed with the mass ratio of 8:0, 5:3, 3:5, 0:8 (denoted as S1, S2, S3, and S4, respectively), and self-assembled with paclitaxel (PTX) to obtain PTX-loaded S1, S2, S3, and S4 nanomicellar assemblies, aiming to realize PTX controlled and on-demand release. Results: The chemical structures of these two copolymers were characterized by gel permeation chromatography (GPC), indicating eight diselenide/disulfide linkages and eight PEG units were contained in these copolymers. Moreover, the thermal-responsive property was detected by UV-vis spectroscopy, meanwhile, the redox-responsive property was observed by TEM in the presence of 10 mM glutathione (GSH). We found that 76.90% of PTX was released from S1 nanomicelles within 23 h. In contrast, this percentage decreased to 64.53% for S4 nanomicelles even the incubation time prolonged to 82 h, indicating explosive and slow release behaviors of S1 and S4 nanomicelles, respectively. In addition, gradually decreased fluorescence intensity around the cellular nucleus was occurred from S1 to S4 orderly, which was consistent with cellular uptake and in vivo anti-tumor experiments. Conclusion: This work not only provides a strategy for the controlled and effective release of PTX, but also improves drug bioavailability in cancer treatment.

show abstract

Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-A for site-specific and controlled drug delivery for cancer therapy

Cited by 58 publications

References 47 publications

Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer

Stimuli-Responsive Drug Delivery Systems for the Diagnosis and Therapy of Lung Cancer

Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist’s Perspective

Tuning Paclitaxel Release Behavior Using Dually-Responsive Nanomicellar Assemblies with Multiple Diselenide/Disulfide Linkages

Contact Info

Product

Resources

About